IL2 and infectious disease: Based on these observations, albeit in the preclinical infectious disease setting, and those from the PIVOT IO 001 study, it is plausible that IL-2 receptor alpha-blocking strategies may inadvertently abrogate the otherwise synergistic effects of combining anti-PD-1 with wild-type IL-2.